Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Jul 14, 2020
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the Company will participate...
-
Jul 9, 2020
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced First-Patient-In (FPI) in the...
-
Jun 30, 2020- Dr. Garret Hampton serves as President, Clinical Sequencing and Oncology at Thermo Fisher Scientific, and held leadership roles at Illumina and Genentech
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics based on Synthetic Lethality, announced...
-
Jun 17, 2020
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a public offering price of $15.00 per share,...
-
Jun 16, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced that it intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In addition, IDEAYA...
-
Jun 16, 2020- Partnership covers three IDEAYA Synthetic Lethality programs - MAT2A, Pol Theta and Werner Helicase, and will explore combinations between IDEAYA and GSK programs
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) and GlaxoSmithKline plc (GSK) announce a strategic partnership in Synthetic Lethality, an emerging field in Oncology. The strategic partnership includes...
-
Jun 11, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Jun 8, 2020
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
May 19, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
May 15, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
May 12, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Apr 21, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Mar 24, 2020
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Mar 18, 2020
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces an update for...
-
Mar 18, 2020Clinical combination of IDE196, a PKC inhibitor, and binimetinib, a MEK inhibitor, to be investigated in patients with solid tumors that harbor GNAQ or GNA11 hotspot mutations, including Metastatic Uveal Melanoma, Cutaneous Melanoma, and Colorectal Cancer
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced that it...
-
Mar 11, 2020
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, today announced an...
-
Jan 15, 2020Chief Executive Officer Yujiro Hata will present key research highlights on Synthetic Lethality today, January 15, 2020, at 5:00 pm PT (8:00 pm ET) at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced key research...
-
Jan 10, 2020
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced that the company has entered...
-
Jan 6, 2020
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the...
-
Dec 18, 2019
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the...
-
Dec 9, 2019- Targeting initiation of Phase 2 single-arm potentially registration-enabling clinical trial in MUM in Q1 2020, potentially coinciding with Phase 2 introduction of tablet formulation
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced further...
-
Nov 20, 2019- Robust enrollment, with 27 total patients enrolled in the Phase 1 dose escalation portion, including 12 patients in MUM DLT cohorts, 14 patients in MUM overflow cohort, and 1 GNA11 cutaneous melanoma patient in non-MUM GNAQ/11 cohort
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced it has...
-
Nov 15, 2019- Update on Phase 1 Dose-Escalation portion of ongoing Phase 1/2 clinical trial, with specific focus on dosing schema, patient enrollment, and safety data, to be presented at SMR on November 20, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that it will...
-
Nov 13, 2019- Single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Nov 5, 2019Dr. Paul Barsanti joins as Vice President, Head of Drug Discovery
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Dr. Paul...
-
Oct 31, 2019- FDA feedback from End‑of‑Phase 1 meeting indicates IDEAYA's proposed single-arm Phase 2 clinical trial may be adequate to support an NDA seeking Accelerated Approval for IDE196 monotherapy in metastatic uveal melanoma (MUM)
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Oct 25, 2019
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Oct 8, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces it has dosed its first...
-
Aug 12, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using...
-
Jul 11, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announces initiation of its Phase 1/2...
-
Jul 9, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA), an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the promotions...
-
May 28, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $10.00 per share. The gross...
-
May 22, 2019
IDEAYA Biosciences, Inc. (Nasdaq:IDYA) today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $10.00 per share, before...
-
May 8, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the U.S. Food and Drug...
-
Mar 29, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that Novartis will present a...
-
Feb 13, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced the appointments of Frank...
-
Jan 2, 2019
IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced that the company is...
-
Dec 4, 2018
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery and development of breakthrough precision medicines, announced today the appointment of Bao Truong,...
-
Oct 23, 2018
IDEAYA Biosciences, Inc., has entered into an exclusive license agreement with Novartis to develop and commercialize Novartis' LXS196, a Phase 1 protein kinase C (PKC) inhibitor for the treatment...
-
Jun 6, 2018
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, today announced that...
-
Jun 5, 2018
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the...
-
Mar 15, 2018Co-led by Nextech Invest, 6 Dimensions Capital, BVF Partners, and Perceptive Advisors
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the...
-
Mar 13, 2018
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced today the...
-
Mar 13, 2018Data related to PARG program to be presented at American Association of Cancer Research (AACR) Annual Meeting
IDEAYA Biosciences, Inc., an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, today announced that it...
-
Jan 5, 2018
IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small-molecule synthetic lethality and immuno-oncology therapies, today announced that...
-
Sep 6, 2017
IDEAYA Biosciences is scheduled to participate in the Emerging Innovators Panel at Citi’s 12th Annual Biotech Conference on Wednesday, September 6, 2017 at the Mandarin Oriental Boston in...
-
Sep 16, 2016
IDEAYA Biosciences, an oncology-focused biotechnology company committed to the discovery of breakthrough small molecule synthetic lethality and immune-oncology therapies, today announced that it...
-
May 3, 2016- Series A investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate
Series A investors include 5AM Ventures, Canaan Partners, Celgene, WuXi Healthcare Ventures, Novartis Institute of Biomedical Research, and Alexandria Real Estate - Small molecule programs with...